Huberman Joins Hims & Hers Board as Peptides Go Mainstream

Andrew Huberman, the Stanford neuroscientist whose health podcast reaches millions monthly, is joining the board of Hims & Hers — and tying one of health media's loudest voices to a company selling many of the treatments he covers.

The deal goes beyond a typical advisor gig. Huberman will formally advise on science and brand marketing, with fiduciary duties and direct strategy involvement, plus separate paid marketing support through his Huberman Lab podcast. His media company, Scicomm Media, will run Hims & Hers podcast ads for payment. He joins a board that includes former Netflix CFO David Wells and former DoorDash CFO Kofi Amoo-Gottfried.

What does this change for his editorial independence?

Huberman's YouTube channel counts more than 8 million subscribers, and his podcast sits among the most popular in its category. Asked whether the arrangement would affect his coverage, he told Business Insider: "We will never filter information differently because of a brand relationship." He said Hims encouraged him to keep educating independent of "any kind of product or platform."

He did not, however, specify how individual episodes, posts, or clips will disclose his board seat and marketing relationship. That gap matters for practitioners watching how creator-commerce deals get disclosed at scale.

The boardroom bet on peptides

Hims & Hers is expanding from hair loss and erectile dysfunction into weight loss, testosterone, preventive care, and peptides. The company signed a deal for a California peptide facility at the end of 2024 and announced the acquisition in February 2025. By May, CEO Andrew Dudum told investors he was following peptide innovation "deeply," citing potential uses in pain management, recovery, and "generalized longevity."

In recent weeks, Hims previewed Peptides+, a site section where consumers could access peptides like BPC-157 — once regulatory approval permits — alongside NAD+ and vitamin B12. The push predates the recent HHS move to temporarily make some buzzy peptides available by prescription.

Huberman has been one of the most prominent mainstream voices on injectable peptides. "I don't know if somebody without an injury needs BPC and TB-500," he said, adding he has no desire to encourage broad peptide use among people who don't need them.

Still, he said a major draw was Hims' plan to control peptide manufacturing from start to finish. "You have to be a channel, not a dam to this kind of information," he said. Dudum countered that personalized health "needs to be navigated extremely carefully and very cautiously."

Why the partnership happened

Huberman reached out to Dudum through a mutual friend, and the two spent six to eight months discussing consumer healthcare's future. "We have some overlapping interests," Huberman said, including bringing "the best healthcare practices to the broadest number of people."

"Joining the board allows me to do that rather than just only talk about how Hims & Hers can do that," he added. Dudum framed the ambition as: "How do you empower the masses around the globe to feel better and take more agency in their life?"

Huberman said Hims fills "this enormous gap that's existed in the middle" between traditional healthcare and high-end concierge care, arguing "the middle 95%" should access personalized care. Competitors including Ro, Midi, longevity clinics, and testing startups are chasing the same middle. Hims brings nearly 3 million existing customers, its own pharmacy, and manufacturing infrastructure.

The bet is that Hims can give consumers a rigorous path through wellness noise. "It really turns people into scientists of themselves," Huberman said. The harder question is whether that rigor survives when one of the voices guiding the audience also sits on the seller's board.